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Pulmonary syndromes in the setting of hepatic disease with portal hypertension include portopulmonary
hypertension (POPH), hepatopulmonary syndrome (HPS) and hepatic hydrothorax. POPH is deﬁned as
pulmonary arterial hypertension with portal hypertension in the absence of other causes of pulmonary
arterial hypertension. HPS is a defect in arterial oxygenation as a result of pulmonary micro vascular
dilatation in the setting of liver disease. We discuss a case of 63-year-old female with liver cirrhosis,
exertional dyspnea and hypoxia associated with coexistence of POPH and HPS. The coexistence of POPH
and HPS is rare entity which can generate a renewal of interest in further understanding the intricate
pathologies behind these diseases.
Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
Pulmonary syndromes in the setting of hepatic disease with
portal hypertension include portopulmonary hypertension (POPH),
hepatopulmonary syndrome (HPS) and hepatic hydrothorax. POPH
is deﬁned as pulmonary arterial hypertension associated with liver
disease and portal hypertension in the absence of other causes. HPS
is deﬁned as classical triad of presence of chronic liver disease or
portal hypertension, arterial deoxygenation and evidence of intra-
pulmonary vascular dilatations. We present a case of liver cirrhosis
where both POPH and HPS were diagnosed simultaneously.2. Case report
A 63-year-old woman came to the emergency department
complaining of a one month history of progressive dyspnea on
exertion and leg swelling. She had a past medical history of hepa-
titis C diagnosed four years ago which was untreated as patient
could not tolerate pegylated interferon. On physical examination,
she was found to be severely hypoxic. Chest was clear to auscul-
tation. Abdominal examination showed hepato-splenomegaly and
ascites. Her chest radiograph revealed mild cardiomegaly without
any evidence of pulmonary edema. High resolution computed
tomography showed a focal area of linear opacities within the right
lower lobe in a reticular patternwith honeycombing and associated: þ1 904 244 3634.
h), ankurgirdhar@yahoo.com
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C BY-NC-ND license.septal thickening. Laboratory data was indicative of chronic liver
disease, including a bilirubin of 2.8, an INR of 1.2, an albumin of 2.8,
and a platelet count of 63,000. Arterial blood gas showed PaO2 of
53mmHgwhile breathing room air. Abdominal ultrasound showed
features suggestive of portal hypertension (ascites, splenomegaly).
Transthoracic echocardiogram revealed an elevated right ventricle
systolic pressure (49 mmHg) accompanied by a mildly dilated right
atrium and right ventricle with normal left ventricular function.
A contrast echocardiogramwas done showing the appearance of
micro bubbles in the left ventricle approximately 6 beats after their
appearance in the right ventricle suggestive of hepatopulmonary
syndrome (HPS). Right heart catheterization was performed which
conﬁrmed pulmonary arterial hypertension (PAH) with a pulmo-
nary artery systolic pressure of 54 mmHg with a mean pulmonary
artery pressure of 39 mmHg, a pulmonary vascular resistance of
266 (dyne*sec)/cm5 a wedge pressure of 15 mmHg and a cardiac
output of 7.2 L/min. Investigation of other causes of pulmonary
hypertension was unrevealing suggesting portopulmonary hyper-
tension (POPH) as a cause of her worsening shortness of breath.
Our patient was treated on oxygen with aggressive diuresis. She
was started on an endothelin receptor A antagonist, Ambrisentan.
There was marked improvement in her shortness of breath and leg
swelling. She was discharged home on oxygen and an endothelin
receptor antagonist.3. Discussion
Pulmonary syndromes in the setting of hepatic disease with
portal hypertension include POPH, HPS and hepatic hydrothorax.1
POPH is deﬁned as pulmonary arterial hypertension with portal
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hypertension.2 HPS is a defect in arterial oxygenation as a result of
pulmonary micro vascular dilatation in the setting of liver disease.8
There is no correlation between portal hypertension and the onset
and severity of POPH.3 In the setting of cirrhosis, the incidence of
HPS and POPH is 4 to 29% and 0 to 7% respectively.1 The coexistence
of POPH and HPS is rare but has been reported previously. So far
there has been only one case report where HPS and POPH were
diagnosed simultaneously.1
The patho-physiology of both HPS and POPH is not clearly
understood. Many theories have been proposed as an explanation
of these alterations in pulmonary hemodynamics. In POPH these
theories include the presence of an increased inﬂammatory
response associated with portal hypertension leading to up-
regulation of endothelin receptors and vasoconstriction without
hypoxemia.1 HPS is associated with vasodilatation causing intra-
pulmonary shunting leading to hypoxemia.3 It is a clinical paradox
that both HPS and POPH coexist as the underlying mechanisms of
the two diseases states are opposite.
Different expressions of endothelin-1 receptor have been
proposed to explain the hemodynamics of both disease entities.
There is an up regulation of endothelin B receptors in HPS leading
to up regulation of nitric oxide synthetase resulting in increase
production of nitric oxide. Nitric oxide causes pulmonary vasodi-
latation, intrapulmonary shunting and hypoxemia.2 HPS is also
associated with orthodeoxia which is deﬁned as oxygen desatura-
tion when assuming the upright position4 and platypnea, deﬁned
as dyspnea induced by the upright position and relieved by
recumbency. In POPH, there is an increased expression of endo-
thelin A receptor leading to vasoconstriction in pulmonary vascu-
lature causing vascular remodeling with the subsequent
development of pulmonary hypertension.1 The high cardiac output
seen with portal hypertension along with pulmonary vasocon-
striction likely plays an important role in the development of
POPH.3
Dyspnea on exertion is the most common symptom of POPH.3
Increased pulmonary artery pressure (PAP) seen on Doppler echo-
cardiography in a patient with portal hypertension is an important
clue towards the diagnosis of POPH. Diagnosis is made by right
heart catheterization and is deﬁned by the presence of the
following features in a patient with portal hypertension; a mean
PAP greater than 25 mmHg at rest or greater than 30 mmHg on
exertion, a raised pulmonary vascular resistance more than
250 dyne/cm2, a transpulmonary gradient (difference between
mean PAP and pulmonary capillary wedge pressure) >12 mmHg
and left ventricular end diastolic pressure of <15 mmHg in the
absence of other causes of PAH.3
The presence of hypoxemia in a patient with portal hyperten-
sion should raise the suspicion of HPS. Usually the PaO2 is less than
80 mmHg and alveolar- arterial gradient is greater than 15 mmHg
on room air.7 Contrast echocardiography is a vital diagnostic tool for
HPS. The appearance of agitated saline in the left atrium after three
cardiac cycles is diagnostic of intrapulmonary shunting.7
POPH and HPS also differ in terms of their treatment options.
Pulmonary vasodilatation is the mainstay of treatment in POPH.
Intravenous epoprostenol has been shown to cause improvement
in hemodynamics and symptoms in POPH but requires constant
intravenous access for drug infusion and a highly compliant
patient.4 Also, both oral and nebulized forms of prostacyclin have
been used in POPH and have demonstrated comparable results to
intravenous prostacyclin.5 The oral dual endothelin receptor
antagonist bosentan has the beneﬁcial effects of improvement inexercise capacity and hemodynamics in POPH. Bosentan blocks
endothelin receptors thereby decreasing the targets for endothelin-
1 levels of which are increased in POPH.4 PAH of any severity in
a cirrhotic patient with portal hypertension carries a poor prog-
nosis and severe PAH carries a high mortality after liver trans-
plantation.3 In many transplant centers, a mean PAP >50 mmHg is
considered as an absolute contraindication for liver trans-
plantation.3 Therefore PAH is generally treated with vasodilators
with the aim of reducing mean PAP below 35 mmHg before liver
transplantation.6 Austin et al. described a case of POPH where the
pulmonary arterial pressure was reduced successfully with triple
therapy including iloprost, sildenaﬁl and bosentan before liver
transplantation.5 The treatment of HPS includes correction of
hypoxemia by oxygen and liver transplantation. Liver trans-
plantation is the only treatment that has been shown to alter the
natural course of the disease with improvement in hypoxemia.7
Patients with refractory hypoxemia carry a higher mortality and
morbidity when undergoing liver transplantation in both the
preoperative and postoperative periods.7
The 5 year survival rate of POPH is 14% without any treatment as
compared to 45% for those who receive medical vasodilator
therapy.6 The 5 year survival for HPS without liver transplant is
23%.7
The treatment strategy in a patient who presents with both HPS
and POPH is challenging. Liver transplantation is required for HPS
but the presence of POPH carries a poor prognosis before and after
liver transplantation. The aim of the treatment is to lower the PAH
with vasodilators before liver transplantation and use oxygen for
hypoxemia. Further studies are needed to understand more about
the patho-physiology of the coexistence of these two syndromes.
There should be a low threshold in getting a contrast echocar-
diogram and right heart catheterization in liver disease patients
with either dyspnea or hypoxemia to investigate the existence of
HPS and/or POPH.
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